MML Investors Services LLC Has $647,000 Position in TransMedics Group, Inc. (NASDAQ:TMDX)

MML Investors Services LLC grew its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 140.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,123 shares of the company’s stock after purchasing an additional 2,407 shares during the period. MML Investors Services LLC’s holdings in TransMedics Group were worth $647,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. International Assets Investment Management LLC acquired a new position in TransMedics Group in the second quarter valued at about $47,000. USA Financial Formulas bought a new position in shares of TransMedics Group in the third quarter valued at approximately $55,000. Quarry LP boosted its holdings in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after acquiring an additional 312 shares in the last quarter. National Bank of Canada FI grew its position in TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after acquiring an additional 262 shares during the last quarter. Finally, Signaturefd LLC increased its holdings in TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Insider Activity at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total value of $1,144,623.75. Following the sale, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,180,642.53. The trade was a 12.27 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the transaction, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 19,417 shares of company stock valued at $2,240,738. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Stock Up 1.9 %

Shares of TransMedics Group stock opened at $61.70 on Friday. TransMedics Group, Inc. has a 1 year low of $59.72 and a 1 year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a market capitalization of $2.07 billion, a P/E ratio of 65.64 and a beta of 2.06. The business has a 50-day moving average of $88.42 and a two-hundred day moving average of $128.78.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. During the same period in the previous year, the company posted ($0.12) earnings per share. TransMedics Group’s revenue for the quarter was up 63.7% compared to the same quarter last year. As a group, equities analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Robert W. Baird reduced their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. TD Cowen lowered their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Oppenheimer reiterated an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a research report on Tuesday, December 3rd. JPMorgan Chase & Co. reissued a “neutral” rating and set a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Finally, Canaccord Genuity Group dropped their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.